Literature review · Ageing & cellular health / Metabolism & weight

NAD+

NAD+ is a metabolic cofactor rather than a peptide. Research on cellular NAD+ biology, NAD+ precursors and direct NAD+ infusion addresses different questions and should not be merged into one efficacy claim.

By HeartPep · Reviewed · 3 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The mechanistic ageing paper primarily concerns cells and mice, including an intervention that raises NAD+ through a precursor. A small direct-infusion human study measured metabolic handling, not longevity, energy benefits or disease treatment.

Identity & scope

Nicotinamide adenine dinucleotide in its oxidised form, NAD+, participates in redox and other cellular reactions. Compounds such as NMN and NR are precursors, not interchangeable names for NAD+.

Catalogue labels covered: NAD+.

What the research shows

  • Gomes and colleagues connected declining nuclear NAD+ with disrupted mitochondrial communication in experimental ageing models.
  • Grant and colleagues tracked plasma and urinary metabolites during and after direct NAD+ infusion, showing substantial metabolic handling before a sustained plasma increase.

Critical interpretation

Concentration, flux and clinical benefit are different endpoints

NAD+ research often moves between circulating concentrations, intracellular pools and enzyme activity. A change in one compartment cannot automatically establish a change in another. The infusion pilot is useful for identifying metabolic handling and future sampling questions, but its design does not supply a counterfactual for improved cognition or ageing. Those outcomes would need their own adequately controlled measurements rather than being inferred from a metabolite curve. [2] [1]

The precursor contrast is informative, not interchangeable

The NMN trial gives an example of a specific human physiological endpoint changing while several broader outcomes do not. Our interpretation is that a positive mechanistic or metabolic signal should stay attached to the actual compound and endpoint. It is not evidence that an equal labelled quantity of NAD+ produces the same exposure or effect. A literature review should therefore extract intervention identity and route before grouping studies under a common NAD biology heading. [3]

A useful next experiment

The unresolved bridge is reproducible exposure to direct NAD+ together with a prespecified functional outcome. Suitable controls, validated handling of unstable metabolites and tissue-relevant measurements would help distinguish target engagement from a clinically useful effect. Longer lifespan is a separate hypothesis, not a synonym for either. [1] [2] [3]

Limitations & uncertainties

  • A precursor intervention cannot directly establish the effect of an NAD+ vial or spray.
  • Changes in metabolite concentrations do not establish a meaningful health outcome.
  • The small infusion pilot does not resolve long-term safety or validate a catalogue formulation.

Open research questions

  • Do sufficiently controlled human trials show durable functional outcomes from direct NAD+ itself?
  • Which analytical measures establish tissue exposure rather than only a change in circulating metabolites?

Selected papers & source records

Download bibliography
Animal studyRelated preparationFull text consulted

1. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging (opens in a new tab)

Gomes AP, Price NL, Ling AJY, et al. (2013). Cell. DOI: 10.1016/j.cell.2013.11.037 (opens in a new tab) · PMID 24360282

Design & population
Cell and mouse experiments investigating SIRT1, NAD+ and nuclear-mitochondrial signalling during ageing.
What the study found
Linked declining NAD+ to altered mitochondrial gene expression and reported reversal of selected mitochondrial changes when NAD+ was raised in old mice.
Limits on interpretation
Mechanistic and precursor-related evidence, not a trial of a direct NAD+ catalogue product.
Human studyNamed compoundFull text consulted

2. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ (opens in a new tab)

Grant R, Berg J, Mestayer R, et al. (2019). Frontiers in Aging Neuroscience. DOI: 10.3389/fnagi.2019.00257 (opens in a new tab) · PMID 31572171

Design & population
Small human metabolic pilot with eleven men, eight receiving NAD+ and three saline controls.
What the study found
Measured time-dependent plasma and urinary NAD+ metabolites; plasma NAD+ did not rise during the first two hours.
Limits on interpretation
Very small, short metabolic study without a clinical efficacy endpoint. It cannot substantiate anti-ageing or cognitive benefit.
Human studyRelated preparationFull text consulted

3. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women (opens in a new tab)

Yoshino M, Yoshino J, Kayser BD, et al. (2021). Science. DOI: 10.1126/science.abe9985 (opens in a new tab) · PMID 33888596

Design & population
Ten-week double-blind placebo-controlled NMN study in 25 postmenopausal women with prediabetes who were overweight or obese, using metabolic clamps and muscle biopsies.
What the study found
Reported increased muscle insulin sensitivity and signalling, without corresponding changes in several body-composition, physical-function or other metabolic measures.
Limits on interpretation
This is an NMN precursor study in a selected population, not direct NAD+ treatment or a longevity trial.

Search & review scope

Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.. Checked 9 November 2026.

Mechanistic NAD+ biology, a small direct-infusion metabolic pilot and a human NMN precursor contrast. Selected full-text sections consulted; the NMN source was also intermittently blocked on direct retrieval.

Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates.

Recorded search terms
  • site:pubmed.ncbi.nlm.nih.gov NAD+ intravenous infusion pilot study plasma urine metabolome 2019 Grant
  • "31572171" "10." Grant
  • "A Pilot Study Investigating Changes" "Grant" 2019 NAD metabolome
  • nicotinamide mononucleotide muscle insulin sensitivity prediabetic women randomized 2021 Yoshino PubMed
  • "10.1016/j.cell.2013.11.037" correction retraction

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. NAD+: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/us/research/library/nad-plus.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes